Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel

Annals of Oncology

Volumn 25, Issue 10, 2014, Pages 2059-2065

  van Hasselt, J G C ^a   van Calsteren, K ^b   Heyns, L ^b   Han, S ^b   Mhallem Gziri, M ^b   Schellens, J H M ^a,c   Beijnen, J H ^a,c   Huitema, A D R ^a   Amant, F ^b,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

anticancer drugs; chemotherapeutics; modeling; pharmacokinetics; pregnancy

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TAXOID;

ADULT; ADVERSE DRUG REACTION; FEMALE; HUMAN; NEOPLASMS; PATHOLOGY; PREGNANCY;

ADULT; DOXORUBICIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIRUBICIN; FEMALE; HUMANS; NEOPLASMS; PACLITAXEL; PREGNANCY; TAXOIDS;

EID: 84918519132     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu140     Document Type: Article

References (24)

1. Amant, F., Van Calsteren, K., Halaska, M.J., et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 13:3 (2012), 256–264.
2. Van Calsteren, K., Heyns, L., De Smet, F., et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 28:4 (2010), 683–689.
3. Anderson, G.D., Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet, 44(10), 2005, 989.
4. Cardonick, E., Iacobucci, A., Use of chemotherapy during human pregnancy. Lancet Oncol 5 (2004), 283–291.
5. Lycette, J.L., Dul, C.L., Munar, M., et al. Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report. Clin Breast Cancer 7 (2006), 342–344.
6. Mir, O., Berveiller, P., Increased evidence for use of chemotherapy in pregnancy. Lancet Oncol 13:9 (2012), 852–854.
7. Van Hasselt, J.G.C., Andrew, M.A., Hebert, M.F., et al. The status of pharmacometrics in pregnancy: highlights from the 3(rd) American Conference on Pharmacometrics. Br J Clin Pharmacol 74:6 (2012), 932–939.
8. Van Hasselt, J.G.C., Green, B., Morrish, G.A., Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women. Pharm Res 29:6 (2012), 1609–1617.
9. Van Hasselt, J.G.C., Allegaert, K., van Calsteren, K., et al. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Res Int 2014 (2014), 1–9 (Article ID 897216).
10. Van Calsteren, K., Verbesselt, R., Ottevanger, N., et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 89:10 (2010), 1338–1345.
11. Joerger, M., Huitema, A.D.R., Richel, D.J., et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46:12 (2007), 1051–1068.
12. Joerger M. Pharmacokinetic and pharmacogenetic profiling in solid cancer patients. PhD Thesis. Utrecht University, Utrecht, Netherlands 2007; http://dspace.library.uu.nl/handle/1874/25430 (16 May 2014, date last accessed).
13. Koolen, S.L.W., Oostendorp, R.L., Beijnen, J.H., et al. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 69:5 (2010), 465–474.
14. Joerger, M., Huitema, A.D.R., Richel, D.J., et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13:21 (2007), 6410–6418.
15. Huizing, M.T., Keung, A.C., Rosing, H., et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:11 (1993), 2127–2135.
16. Innocenti, F., Iyer, L., Ramírez, J., et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:5 (2001), 686–692.
17. Davison, J.M., Hytten, F.E., Glomerular filtration during and after pregnancy. J Obstet Gynaecol Br Commwlth 81:8 (1974), 588–595.
18. Rochat, B., Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:4 (2005), 349–366.
19. Gligorov, J., Lotz, J.P., Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9:Suppl 2 (2004), 3–8.
20. Larsson, A., Palm, M., Hansson, L.-O., et al. Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta Obstet Gynecol Scand 87:10 (2008), 1084–1088.
21. Amant, F., von Minckwitz, G., Han, S.N., et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an International Collaborative Study. J Clin Oncol, 2013 April 22 [epub ahead of print], doi: 10.1200/JCO.2012.45.6335.
22. Loibl, S., Han, S.N., von Minckwitz, G., et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol 13:9 (2012), 887–896.
23. van Hasselt, J.G.C., Gupta, A., Hussein, Z., et al. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia. Br J Clin Pharmacol 76:6 (2013), 2878–2881.
24. van Hasselt, J.G.C., Boekhout, A.H., Beijnen, J.H., et al. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clin Pharmacol Ther 90:1 (2011), 126–132.